3rd May 2006 07:01
Bespak PLC03 May 2006 For immediate release 3 May 2006 Bespak plc Trading update for the 52 weeks to 29 April 2006 Bespak plc (LSE: BPK), a leader in specialty medical devices, announces thattrading finished strongly in the 52 weeks to 29 April 2006 and was ahead of itsexpectations for the year. Manufacturing has commenced for the Exubera(R)inhalation device following regulatory approval in the US and Europe, and KingSystems Corporation, the US respiratory products supplier acquired in December2005, has performed ahead of plan. Looking ahead, a number of key issues will influence Bespak's performance:manufacturing will continue to be scaled-up for the Exubera(R) inhalation devicein preparation for its global launch; there will be the full year tradingbenefit of the King acquisition; and customers are initiating plans to convertfrom CFC to HFA in albuterol formulations in the US and we could benefit frominventory building in the short term in advance of conversion. Bespak will report its final results on 12 July 2006. For further information, please contact: Bespak plc Tel: +44 (0) 1908 525 241Mark Throdahl - Chief ExecutiveMartin Hopcroft - Group Finance Director Buchanan Communications Tel: +44 (0) 20 7466 5000Tim Thompson / Mark Court / Mary-Jane Johnson About Bespak plc Bespak, a leader in specialty medical devices, develops delivery systems for thepharmaceutical industry and disposable airway management products for criticalcare settings. Bespak's product range includes metered dose and dry powderinhalers, actuators, inflation valves, breathing circuits, disposable face masksand laryngeal tubes. The group, which has facilities in King's Lynn and MiltonKeynes in the UK and Indianapolis and Kent, Ohio, in the US, is quoted on theOfficial List of the London Stock Exchange (LSE: BPK). For more information,please visit www.bespak.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
CSRT.L